Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AKG-210
- Development stage
- Preclinical
- Lead developer
- Akagera Medicines
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
01
Overview
AKG-210 is a preclinical mRNA-based prophylactic vaccine candidate being developed by Akagera Medicines for the prevention of Respiratory Syncytial Virus (RSV) infection. As an mRNA vaccine, it is designed to deliver genetic instructions to host cells to express specific viral antigens, which then stimulate the immune system to produce a protective response against the virus. AKG-210 is part of Akagera's broader pipeline of mRNA vaccines targeting infectious diseases, leveraging proprietary delivery technologies to optimize stability and immunogenicity.
- Other names
- RSV mRNA-LNP vaccineLigand-directed mRNA-LNP RSV vaccine
Beyond the preview
Go deeper on AKG-210.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AKG-210.